Abstract Number: 1430 • 2012 ACR/ARHP Annual Meeting
Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Coronary Artery Calcium (CAC)Than Women without SLE
Background/Purpose: Women with SLE have increased rates of subclinical atherosclerosis and cardiovascular (CV) events. We sought to determine which risk factors may be significant in…Abstract Number: 1431 • 2012 ACR/ARHP Annual Meeting
Single Photon Emission Computed Tomography Contributes to Clinical Assessments in Neuropsychiatric Systemic Lupus Erythematosus Patients
Background/Purpose: Because the clinical manifestations of NPSLE are diverse, multifaceted approaches are necessary to evaluate the disease activity and therapeutic responses. We investigated contribution of…Abstract Number: 1432 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Etanercept in Systemic LUPUS Erythematosus
Background/Purpose: TNF is a strong mediator of inflammation with a controversial role in SLE. Whereas few open-label studies have shown efficacy of anti-TNFα agents in…Abstract Number: 1433 • 2012 ACR/ARHP Annual Meeting
Persistent Dyslipidemia Is a Risk Factor of Progression to Chronic Kidney Disease in Patients with Lupus Nephritis
Background/Purpose: To investigate the effect of dyslipidemia at baseline and during follow-up period on the progression to chronic kidney disease (CKD) in patients with biopsy-proven…Abstract Number: 1434 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Morbidity in a Long-Term Follow-up Cohort of Systemic Lupus Erythematosus Patients in Southern Sweden
Background/Purpose: The main objective was to study the incidence of myocardial infarction in a cohort of patients with Systemic Lupus Erythematosus (SLE) assembled prospectively over…Abstract Number: 1435 • 2012 ACR/ARHP Annual Meeting
Identifying Systemic Lupus Erythematosus Patients At Higher Risk of Coronary Artery Disease
Background/Purpose: There is a high prevalence of premature atherosclerosis among patients with SLE. The traditional Framingham risk score (FRS) identifies few of the SLE patients…Abstract Number: 1396 • 2012 ACR/ARHP Annual Meeting
Associates of a History of Thrombosis in Systemic Lupus Erythematosus
Background/Purpose: Thrombosis in SLE is highly associated with antiphospholipid antibodies, yet the majority of those with antiphospholipid antibodies never have a thrombotic event. Plasma microparticles…Abstract Number: 1397 • 2012 ACR/ARHP Annual Meeting
Risk Factors Associated with Early Central Nervous System Damage Detected Through Perfusion MRI in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid antibodies (aPL), hypertension and accumulated damage (SLICC-DI) have been associated to the severity of cerebral MRI lesions and to cognitive deficits in SLE.…Abstract Number: 1398 • 2012 ACR/ARHP Annual Meeting
Inflammatory Back Pain Is Increased in SLE and Associated with Anti-Sm Antibodies
Background/Purpose: Growing evidence suggest that autoantibodies may present in patients with ankylosing spondylitis. Here, we aim to determine the association of inflammatory back pain and…Abstract Number: 1399 • 2012 ACR/ARHP Annual Meeting
Regional Fat Distribution Is Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Female Patients
Background/Purpose: In general population, a higher trunk fat and the ratio of trunk fat to leg fat (trunk-leg ratio) increase the risk for a cardiovascular…Abstract Number: 1400 • 2012 ACR/ARHP Annual Meeting
Predictors of Obesity in Systemic Lupus Erythematosus
Background/Purpose: Hypertension and obesity are the two most important traditional cardiovascular risk factors in the prediction of subclinical measures of atherosclerosis in SLE. Obesity is…Abstract Number: 1401 • 2012 ACR/ARHP Annual Meeting
Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus
Background/Purpose: Photosensitivity (PS) is one of the most common manifestations of systemic lupus erythematosus (SLE), and is 1 of only 11 criteria used to make…Abstract Number: 1402 • 2012 ACR/ARHP Annual Meeting
Anti-ApoA1 Antibodies Associate with Disease Activity in Lupus and Are Lower in Patients Taking Hydroxychloroquine: A Longitudinal Analysis of 398 Samples
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a significantly increased risk of developing cardiovascular disease. The presence of chronic inflammation which characterizes SLE…Abstract Number: 1403 • 2012 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies Are Associated with Disease Activity and Hydroxychloroquine Use in Patients with Lupus: A Longitudinal, Multivariate Analysis of 398 Samples
Background/Purpose: Impaired apoptotic clearance appears to play a pivotal role in the pathogenesis of SLE leading to the accumulation of nuclear debris, such as nucleosomes,…Abstract Number: 1404 • 2012 ACR/ARHP Annual Meeting
There Is an Association Between Disease Activity and Risk of Thromboembolism in SLE
Background/Purpose: Venous thromboembolism is a recognized complication of systemic lupus erythematosus (SLE). The role of antiphospholipid antibodies (aPL) in thrombogenesis is well documented; much less…